The association between co-morbidity and the use of antidiabetics or adjunctive cardiovascular medicines in Australian veterans with diabetes

Diabetes Research and Clinical Practice

Volumn 91, Issue 1, 2011, Pages 115-120

  Zhang, Ying ^a   Vitry, Agnes ^b   Caughey, Gillian ^b   Roughead, Elizabeth E ^b   Ryan, Philip ^a   Gilbert, Andrew ^b   Shakib, Sepehr ^a,c   McDermott, Robyn ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Ageing; Antidiabetics; Cardiovascular risk; Co morbidity; Diabetes

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONYLUREA; WARFARIN;

AGED; ARTICLE; ASTHMA; AUSTRALIA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG UTILIZATION; DYSLIPIDEMIA; FEMALE; HEART FAILURE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRACTICE GUIDELINE; VETERAN;

AGED; AGED, 80 AND OVER; AGING; AUSTRALIA; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DATABASES, FACTUAL; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; RISK; VETERANS; VETERANS HEALTH;

EID: 78650578377     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.10.006     Document Type: Article

References (30)

1. AIHW. Diabetes: Australian facts 2008. Canberra. Available from: http://www.aihw.gov.au/publications/cvd/daf08/.
2. Hoerger T., Ahmann A. The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes. J Manag Care Pharm 2008, 14(1 Suppl. C):S2-S14.
3. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259. Heart Outcomes Prevention Evaluation Study Investigators.
4. Kober L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995, 333:1670-1676.
5. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992, 327:669-677.
6. Aspirin therapy in diabetes (position statement). Diabetes Care 2004, 27:s72-s73. American Diabetes Association.
7. Costa J., Borges M., David C., Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006, 332:1115-1124.
8. Vijan S., Hayward R.A. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004, 140:650-658.
9. Malesker M.A. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities. Pharmacotherapy 2008, 28:193-206.
10. Caughey G.E., Vitry A.I., Gilbert A.L., Roughead E.E. Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health 2008, 8:221.
11. Munshi M. Managing the "geriatric syndrome" in patients with type 2 diabetes. Consult Pharm 2008, 23(Suppl. B):12-16.
12. Balkrishnan R., Rajagopalan R., Camacho F.T., Huston S.A., Murray F.T., Anderson R.T. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003, 25:2958-2971.
13. Cooke C.E., Fatodu H. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization. J Manag Care Pharm 2006, 12:649-655.
14. Gonzalez J.S., Safren S.A., Cagliero E., Wexler D.J., Delahanty L., Wittenberg E., et al. Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diabetes Care 2007, 30:2222-2227.
15. Rosen M.I., Beauvais J.E., Rigsby M.O., Salahi J.T., Ryan C.E., Cramer J.A. Neuropsychological correlates of suboptimal adherence to metformin. J Behav Med 2003, 26:349-360.
16. Kalsekar I.D., Madhavan S.S., Amonkar M.M., Douglas S.M., Makela E., Elswick B.L., et al. Impact of depression on utilization patterns of oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes mellitus: a retrospective cohort analysis. Clin Ther 2006, 28:306-318.
17. Caughey G.E., Roughead E.E., Vitry A.I., McDermott R.A., Shakib S., Gilbert A.L. Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Pract 2010, 87:385-393.
18. Roughead E.E., Pratt N., Gilbert A.L. Trends over 5 years in cardiovascular medicine use in Australian veterans with diabetes. Br J Clin Pharmacol 2007, 64:100-104.
19. Anatomical therapeutic chemical code classification index with defined daily doses 2004, World Health Organization, World Health Organization Collaborating Centre for Drug Statistics Methodology, Oslo.
20. Sloan K., Sales A., Liu C., Fishman P., Nichol P., Suzuki N., et al. Construction and characteristics of the R×Risk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care 2003, 41:761-774.
21. Vitry A., Wong S.A., Roughead E.E., Ramsay E. Validity of medication-based comorbidity indices in the Australian elderly population. Aust NZ J Public Health 2009, 33:126-130.
22. Australian Bureau of Statistics. SEIFA-Socio-Economic Indexes for Areas; 2006. Available from: (accessed March 2008). http://www.abs.gov.au/websitedbs/D3310114.nsf/home/Seifa_entry_page.
23. Feise R.J. Do multiple outcome measures require p-value adjustment?. BMC Med Res Methodol 2002, 2(8). 10.1186/1471-2288-2-8.
24. Zhang Y., Vitry A., Roughead E., Ryan P., Gilbert A. Co-morbidity and the utilisation of health care for Australian veterans with diabetes. Diabetic Med 2010, 27:65-71.
25. Weekes A.J., Thomas M.C. The use of oral antidiabetic agents in primary care. Aust Fam Phys 2007, 36:477-480.
26. Thomas M.C., Weekes A.J., Broadley O.J., Cooper M.E., Mathew T.H. The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust 2006, 185:140-144.
27. Wen Y.K. Impact of acute kidney injury on metformin-associated lactic acidosis. Int Urol Nephrol 2009, 41:967-972.
28. Australian medicine handbook 2009, Australian Medicines Handbook Pty Ltd., Adelaide, South Australia. S. Rossi (Ed.).
29. Veitch Perter C., Clifton-Bligh Rory J. Long-acting sulfonylureas - long-acting hypoglycaemia. MJA 2004, 180:84-85.
30. Furuhashi T., Moroi M., Joki N., Hase H., Masai H., Kunimasa T., et al. The impact of chronic kidney disease as a predictor of major cardiac events in patients with no evidence of coronary artery disease. J Cardiol 2010, 55:328-336.